Evaluation of Fatty Liver
Adults with suspected fatty liver should undergo risk stratification using the FIB-4 score (calculated from age, ALT, AST, and platelets) as the initial assessment, followed by liver stiffness measurement via transient elastography for those with indeterminate or high scores, without requiring routine ultrasound imaging in high-risk groups. 1, 2, 3
Initial Patient Identification
Target the following high-risk groups for evaluation 1, 2, 3:
- Type 2 diabetes or prediabetes (>70% prevalence of NAFLD)
- Obesity and/or metabolic syndrome components (central obesity, hypertension, dyslipidemia)
- Elevated aminotransferases (ALT or AST >30 IU/L)
- Incidental hepatic steatosis on imaging (especially with abnormal liver enzymes)
Step-by-Step Diagnostic Algorithm
Step 1: History and Laboratory Assessment
Obtain the following 2:
- Alcohol consumption history: Define significant use as ≥21 drinks/week (men) or ≥14 drinks/week (women) over 2 years 4
- Complete blood count (for platelet count)
- Comprehensive metabolic panel (AST, ALT, albumin, bilirubin, alkaline phosphatase)
- Exclude competing liver diseases:
- Hepatitis C antibody with reflex HCV RNA
- Hepatitis B surface antigen (HBsAg), antibodies
- Consider: ANA, AMA, ASMA, immunoglobulins, ferritin, alpha-1 antitrypsin
Critical caveat: Mildly elevated ferritin is common in NAFLD and does not indicate iron overload. However, elevated ferritin with increased transferrin saturation plus HFE C282Y homozygote/compound heterozygote mutations warrants liver biopsy 5, 4, 6.
Step 2: Fibrosis Risk Stratification with FIB-4
Calculate FIB-4 score (age × AST) / (platelet count × √ALT) using mdcalc.com 2, 3, 7:
- FIB-4 <1.3 (<2.0 if age >65): Low risk—repeat testing in 2-3 years, no further workup needed 2
- FIB-4 1.3-2.67: Indeterminate risk—proceed to Step 3
- FIB-4 >2.67: High risk—proceed to Step 3
Why FIB-4? It has the best diagnostic accuracy (AUROC 0.78-0.80) for advanced fibrosis compared to other simple scores, with excellent negative predictive value (≥90%) for ruling out advanced disease 1, 2, 7. The 2023 American Diabetes Association guidelines specifically endorse FIB-4 as the screening tool even in patients with normal liver enzymes 3.
Step 3: Secondary Assessment with Liver Stiffness Measurement
For indeterminate or high FIB-4, obtain vibration-controlled transient elastography (VCTE/FibroScan) 1, 2:
- LSM <8 kPa: Low risk—repeat in 2-3 years
- LSM 8-12 kPa: Indeterminate—refer to hepatologist for monitoring
- LSM >12 kPa: High risk for advanced fibrosis—refer to hepatologist for possible MR elastography or liver biopsy
Alternative if VCTE unavailable: Enhanced Liver Fibrosis (ELF) test or ultrasound shear wave elastography 1, 7. MR elastography has excellent performance but is less accessible 7.
Imaging Considerations
Do NOT routinely obtain ultrasound for diagnosis in high-risk groups (diabetes, obesity, metabolic syndrome) where pretest probability of steatosis exceeds 70% 1, 2. Move directly to fibrosis risk stratification with FIB-4.
Exception: Ultrasound is reasonable for patients with incidentally discovered steatosis who need confirmation, or when evaluating for mass lesions in those with elevated aminotransferases 2.
Ultrasound has high accuracy for moderate-to-severe steatosis but poor sensitivity for mild steatosis 2. Controlled attenuation parameter (CAP) via FibroScan can quantify steatosis and fibrosis simultaneously, making it preferable when available 1.
When to Consider Liver Biopsy
Liver biopsy remains the gold standard but should be reserved for specific situations 8, 5, 6:
- Indeterminate or high-risk results on noninvasive testing requiring definitive staging
- Competing etiologies that cannot be excluded without histology
- Suspected autoimmune overlap: High autoantibody titers (ANA >1:160, ASMA >1:40) with very elevated aminotransferases (>5× ULN) or high globulins 5, 6
- Genetic hemochromatosis: HFE C282Y homozygote/compound heterozygote with elevated iron studies 5, 4
- Clinical trial enrollment or when histology would change management
Assessment of Metabolic Comorbidities
- Cardiovascular risk: Lipid panel, blood pressure, waist circumference, BMI
- Diabetes screening: Fasting glucose and/or HbA1c
- Other associations: Hypothyroidism, polycystic ovary syndrome, obstructive sleep apnea
Common Pitfalls to Avoid
Don't rely on aminotransferases alone: Normal ALT/AST does not exclude advanced fibrosis—up to 20% of patients with significant fibrosis have normal enzymes 3
Age-adjust FIB-4 cutoffs: Use <2.0 (not <1.3) as the low-risk threshold in patients >65 years to avoid false positives 2
Don't screen asymptomatic family members: Systematic family screening is not recommended despite genetic susceptibility 6
Avoid unnecessary liver biopsies: In asymptomatic patients with incidental steatosis and normal liver biochemistries, biopsy cannot be recommended 4
Don't dismiss low autoantibody titers: ANA >1:160 or ASMA >1:40 occurs in 21% of NAFLD patients and is typically an epiphenomenon, but very high titers with other autoimmune features require further workup 5, 6
Monitoring Strategy
- Low-risk patients (FIB-4 <1.3 and LSM <8 kPa): Repeat noninvasive testing every 2-3 years 2
- Indeterminate/high-risk patients: Refer to hepatology for specialized monitoring and consideration of emerging therapies 3, 2
- Patients with persistently elevated aminotransferases >6 months despite low FIB-4: Evaluate for other liver diseases 3
This two-tier approach (FIB-4 followed by elastography) provides cost-effective risk stratification while avoiding unnecessary imaging and biopsies in the majority of patients 2, 7.